This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Periostat SR, Col-101, doxycycline
Description: Periostat MR is a new, once-daily, modified release formulation of Periostat, CollaGenex's lead product for the treatment of adult periodontitis.
Periostat is a formulation of doxycycline, an antibiotic that disrupts protein synthesis by binding to the 30S sub-unit of the protein synthesis machinery.
Deal Structure: In February 2008, CollaGenex Pharmaceuticals announced that it entered into a definitive merger agreement with an affiliate of Galderma Pharma S.A. Upon completion of the merger, CollaGenex will become a wholly-owned subsidiary of Galderma.
In April 2008, CollaGenex became a wholly-owned subsidiary of Galderma.
Periostat MR News
Additional information available to subscribers only: